The Europe cannabidiol market size was estimated at USD 415.6 million in 2025 and is predicted to increase from USD 481.39 million in 2026 to approximately USD 1806.7 million by 2035, expanding at a CAGR of 15.83% from 2026 to 2035. The market is growing steadily due to increasing acceptance of CBS-based wellness and pharmaceutical products, along with rising consumer awareness regarding pain management, anxiety relief, and skincare applications. Expanding legalization frameworks and strong demand for hemp-derived products across countries such as Germany, the UK, and France are further supporting regional market growth.
Cannabidiol is a naturally occurring non-psychoactive compound found in the cannabis plant, widely used in wellness, pharmaceutical, and therapeutic products for its potential calming and pain-relieving properties. The Europe cannabidiol market is growing rapidly due to increasing consumer preference for natural wellness products, rising awareness about CBD’s potential benefits in stress relief, pain management, and skincare, and supportive legalization of hemp-derived products across several European countries. Growing investments in pharmaceutical research, expanding e-commerce distribution, and rising demand for medical cannabis products are further accelerating market expansion across the region.
AI can significantly transform the market by improving product development, quality control, and supply chain efficiency through data-driven insights and predictive analytics. It helps companies understand consumer preferences, optimize CBD formulations, and ensure regulatory compliance more effectively. AI-powered marketing and personalized wellness recommendations also enhance customer engagement, while automation in cultivation and extraction processes reduces costs and increases production efficiency across the value chain.
| Table | Scope |
| Market Size in 2026 | USD 481.39 Million |
| Projected Market Size in 2035 | USD 1806.7 Million |
| CAGR (2026 - 2035) | 15.83% |
| Historical Data | 2020 - 2023 |
| Base Year | 2025 |
| Forecast Period | 2026 - 2035 |
| Measurable Values | USD Millions/Units/Volume |
| Market Segmentation | By Source, By Product Type, By Nature, By Application, By Distribution Channel, By End User, By Region |
| Top Key Players | Bedrocan International, Stenocare A/S, PharmaHemp, Endoca, Kanabo Group |
| Segment | Share 2025 (%) |
| Hemp | 78% |
| Marijuana | 22% |
The Hemp Segment Dominated the Europe Cannabidiol Market in 2025
The hemp segment held a dominant share of 78% in 2025 and is expected to grow at the fastest CAGR in the Europe cannabidiol market during the forecast period due to its legal acceptance under EU regulations, when THC levels are within permitted limits, making it widely accessible for commercial use. Hemp is cost-effective to cultivate, scalable for large production, and offers consistent CBD extraction quality. Increasing consumer preference for natural, non-psychoactive wellness products and strong demand from cosmetics, food, and pharmaceutical industries further strengthen its dominance.
The marijuana segment held the second-largest share of 22% in 2025 due to its strong therapeutic applications in chronic pain, epilepsy, cancer-related symptoms, and neurological disorders. Growing physician acceptance, expanding clinical research, and increasing government approvals for medical cannabis use are driving demand. However, stricter regulations compared to hemp-derived CBD limit wider accessibility, keeping its market share below the more widely available hemp segment.
| Segment | Share 2025 (%) |
| Oils | 29% |
| Tinctures | 11% |
| Capsules & Softgels | 13% |
| Edibles | 18% |
| Topicals | 14% |
| Vapes | 7% |
| CBD Isolates | 5% |
| Pet CBD Products | 3% |
The Oils Segment Led the Market in 2025 with the Largest Share
The oils segment led the Europe cannabidiol market with a share of 29% in 2025 due to its high versatility, fast absorption, and ease of consumption in both medical and wellness applications. CBD oils allow precise dosage control, making them widely preferred by consumers for stress relief, pain management, and sleep support. Strong availability through online and retail channels, along with widespread use in pharmaceutical and personal care products, further strengthens its dominant market position.
The edibles segment held the second-largest share of 18% in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period due to increasing consumer preference for convenient, tasty, and discreet CBD consumption options. Products like gummies, chocolates, and beverages offer easy dosing without the earthy taste of oils. Rising demand among younger consumers, expanding retail availability, and strong adoption in wellness and relaxation products further support the steady growth of CBD edibles across Europe.
The topicals segment held a 14% of Europe cannabidiol market share due to the rising demand for targeted pain relief, skincare, and anti-inflammatory applications. CBD-infused creams, balms, and lotions are increasingly used for conditions like muscle soreness, arthritis, and skin disorders. Growing consumer interest in natural and organic skincare solutions, along with expanding availability in pharmacies and beauty retail channels, is further driving strong adoption of CBD topicals across Europe.
The capsules & softgels segment held a 13% of market share due to rising demand for precise, pre-measured, and easy-to-consume CBD dosing options. Consumers prefer them for their convenience, tasteless nature, and consistent effects in daily wellness routines. Increasing use for stress, sleep, and chronic pain management, along with growing acceptance in pharmaceutical applications and expanding retail availability, is driving steady growth across Europe.
| Segment | Share 2025 (%) |
| Organic | 61% |
| Conventional | 39% |
The Organic Segment Led the Market in 2025 with the Largest Share
The organic segment held a dominant share of 61% in 2025 and is expected to grow at the fastest CAGR in the Europe cannabidiol market during the forecast period due to strong consumer preference for clean-label, chemical-free, and sustainably sourced CBD products. Growing healthcare consciousness, stricter quality standards, and rising demand for premium wellness and skincare solutions further drive adoption. Organic certification also builds higher trust and product credibility, allowing manufacturers to charge premium prices. Expanding availability across retail and e-commerce channels strengthens its leading market position.
The conventional segment held the second-largest share of 39% in its lower production costs, higher scalability, and easier cultivation methods compared to organic CBD. It ensures a stable and cost-efficient supply of raw material for manufacturers, supporting large-scale production. Strong demand from price-sensitive consumers, along with widespread use in food, cosmetics, and wellness products, further drives consistent growth of conventional CBD across Europe.
| Segment | Share 2025 (%) |
| Medical | 41% |
| Wellness & Lifestyle | 24% |
| Cosmetics & Personal Care | 18% |
| Food & Beverage | 11% |
| Pet Care | 6% |
The Medical Segment Led the Europe Cannabidiol Market in 2025 with the Largest Share
The medical segment held a dominant share of 41% in 2025 due to strong therapeutic use of CBD in managing chronic pain, epilepsy, anxiety, and neurological disorders. Increasing clinical research, growing physician acceptance, and supportive regulatory approvals for medical cannabis are driving demand. Hospitals and healthcare providers are increasingly integrating CBD-based treatments, while rising patient awareness about alternative therapies further strengthens the dominance of the medical application segment across Europe.
The wellness & lifestyle segment held the second-largest share of 24% in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period due to rising consumer interest in natural stress relief, relaxation, sleep improvements, and overall well-being. Increasing adoption of CBD in daily routines through oils, edibles, and skincare products is driving demand. Strong growth of the self-care trend, expanding e-commerce availability, and wider acceptance of plant-based wellness solutions further support this segment’s expansion across Europe.
The cosmetics & personal care segment held a 18% of Europe cannabidiol market share due to rising demand for natural, plant-based skincare products with anti-inflammatory, antioxidant, and anti-aging properties. Consumers are increasingly choosing CBD-infused creams, lotions, and serums for acne, eczema, and skin hydration. Expanding beauty industry innovation, strong clean-beauty trends, and wider availability through retail and online channels are further accelerating segment growth across Europe.
The food & beverage segment held a 11% of market share due to rising consumer demand for functional and wellness-oriented products such as CBD-infused beverages, snacks, and dietary supplements. Increasing interest in stress relief, relaxation, and sleep support through everyday consumption is driving adoption. Growing product innovation, expanding legalization of hemp-derived CBD in foods, and strong retail penetration are further accelerating segment growth across Europe.
| Segment | Share 2025 (%) |
| Online Retail | 36% |
| Pharmacies & Drug Stores | 24% |
| Specialty Stores | 16% |
| Supermarkets & Hypermarkets | 11% |
| Wellness Clinics | 8% |
| Convenience Stores | 5% |
The Online Retail Segment Dominated the Market in 2025
The online retail segment led the Europe cannabidiol market with a share of 36% in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period due to its wide product availability, discreet purchasing experience, and convenience of home delivery. Consumers prefer e-commerce platforms for comparing brands, accessing detailed product information, and purchasing CBD products without stigma. Strong digital marketing direct-to-consumer sales models and expanding internet penetration across Europe further support that online channels are the leading distribution mode in the CBD market.
The pharmacies & drug stores segment held the second-largest share of 24% in 2025due to high consumer trust, professional guidance, and assurance of product quality and safety. These channels are preferred for purchasing medically oriented CBD products, especially for pain, anxiety, and sleep-related conditions. Strong regulatory compliance, easy accessibility, and growing pharmacist recommendations further strengthen their position in the European CBD distribution landscape.
The specialty stores segment held a 16% of Europe cannabidiol market share due to increasing demand for expert-guided product selection of CBD offerings. These stores provide personalized recommendations, detailed product knowledge, and a curated range of high-quality CBD items. Rising consumer interest in niche wellness products, trust in in-store consultations, and availability of diverse formulations further drive the strong growth of specialty retail channels across Europe.
The supermarkets & hypermarkets segment held a 11% of market share due to rising consumer preference for convenient one-stop shopping and easy product accessibility. These retail outlets offer high product visibility, a trusted brand’s presence, and competitive pricing for CBD wellness items. Increasing shelf space for health and wellness products, along with growing mainstream acceptance of CBD, is further driving strong growth in this distribution channel across Europe.
The global cannabidiol market size is calculated at USD 10.39 billion in 2025, grew to USD 12.03 billion in 2026, and is projected to reach around USD 45.17 billion by 2035. The market is expanding at a CAGR of 15.83% between 2026 and 2035.
The UK cannabidiol market is growing rapidly due to strong consumer awareness, increasing acceptance of CBD-based wellness products, and a well-developed retail and e-commerce ecosystem. Clearer regulatory guidance on hemp-derived CBD has encouraged product launches and investments. High demand for stress relief, sleep support, and pain management solutions, along with widespread availability in pharmacies, health stores, and online platforms, further strengthened market growth in the UK.
The Germany cannabidiol market is expanding due to strong legalization support for medical cannabidiol, increasing physician prescriptions, and rising patient awareness of CBD’s therapeutic benefits. High prevalence of chronic pain, anxiety, and neurological disorders is boosting demand. Germany’s well-established pharmaceutical sector, advanced healthcare infrastructure, and growing availability of CBD products through pharmacies and online channels are further driving consistent market growth across the country.
R&D
Clinical Trials
Patient Support and Services
| Companies | Headquarters | Offerings |
| Bedrocan International | Netherlands | Standardized medical cannabis products, pharmaceutical-grade CBD/THC formulations for prescription use. |
| Stenocare A/S | Denmark | Medical cannabis oils and CBD-based prescription therapies are distributed through pharmacies. |
| PharmaHemp | Slovenia | Hemp-derived CBD oils, isolates, cosmetics, and nutraceutical wellness products. |
| Endoca | Denmark | Organic CBD oils, capsules, raw hemp extracts, and wellness supplements. |
| Kanabo Group | United Kingdom | Medical cannabis inhalation systems, CBD vape products, and digital cannabis healthcare solutions. |
Strengths
Weaknesses
Opportunities
Threats
By Source
By Product Type
By Nature
By Application
By Distribution Channel
By End User
By Region
Principal Consultant
Rohan Patil is a seasoned market research professional with over 5+ years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.
Learn more about Rohan Patil
Reviewed By
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.
Learn more about Aditi Shivarkar
+1 804-441-9344
